Regulatory & Safety

(Image: Getty/Radachynskyi)

Recro spins out Baudax to boost CDMO focus

By Vassia Barba

Recro Pharma announces the separation of its acute care business to launch Baudax Bio as a developer of products, including non-opioid analgesics, to concentrate on its CDMO business.

(Image: Getty/Elen11)

The scale of generic uptake in the major markets

By Ben Hargreaves

The divergence across global market penetration of generic medicines is broad, with some countries’ markets worth close to half of the entire sector or as low as one fifth, according to IGBA.

(Image: Getty/Master1305)

WuXi STA’s facility passes first inspection by EMA

By Ben Hargreaves

The company’s Shanghai facility passes the European regulator’s inspection with no ‘critical’ or ‘major’ findings regarding the commercial products produced at the site.

Follow us

Products

View more

Webinars